Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 15 | 2025 | 61 | 1.720 |
Why?
|
| Glioblastoma | 11 | 2025 | 281 | 1.280 |
Why?
|
| Fracture Healing | 5 | 2014 | 43 | 1.050 |
Why?
|
| Ethanol | 6 | 2012 | 273 | 0.830 |
Why?
|
| Tibial Fractures | 4 | 2014 | 44 | 0.690 |
Why?
|
| beta Catenin | 2 | 2014 | 265 | 0.690 |
Why?
|
| Brain Neoplasms | 6 | 2023 | 813 | 0.600 |
Why?
|
| Bony Callus | 2 | 2014 | 5 | 0.480 |
Why?
|
| Wnt Signaling Pathway | 2 | 2014 | 103 | 0.480 |
Why?
|
| Growth Plate | 1 | 2014 | 11 | 0.430 |
Why?
|
| Aggrecans | 1 | 2014 | 43 | 0.430 |
Why?
|
| Chondrocytes | 1 | 2014 | 66 | 0.430 |
Why?
|
| Lithium Chloride | 1 | 2014 | 3 | 0.420 |
Why?
|
| Binge Drinking | 1 | 2014 | 15 | 0.410 |
Why?
|
| Extremities | 1 | 2014 | 176 | 0.390 |
Why?
|
| Kynurenine | 5 | 2022 | 23 | 0.350 |
Why?
|
| Tryptophan | 7 | 2022 | 105 | 0.330 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 665 | 0.320 |
Why?
|
| Glioma | 2 | 2022 | 301 | 0.300 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1621 | 0.270 |
Why?
|
| Animals | 25 | 2023 | 28155 | 0.270 |
Why?
|
| Osteoporosis | 1 | 2008 | 129 | 0.260 |
Why?
|
| Bone Density | 1 | 2008 | 237 | 0.260 |
Why?
|
| Mice | 13 | 2023 | 12269 | 0.260 |
Why?
|
| Brain | 3 | 2020 | 2391 | 0.210 |
Why?
|
| Drug Design | 1 | 2025 | 133 | 0.210 |
Why?
|
| Proteolysis | 1 | 2025 | 123 | 0.210 |
Why?
|
| Immunotherapy | 4 | 2018 | 761 | 0.200 |
Why?
|
| Oncolytic Viruses | 1 | 2022 | 20 | 0.190 |
Why?
|
| Femoral Fractures | 2 | 2011 | 34 | 0.170 |
Why?
|
| Alcoholic Intoxication | 2 | 2011 | 37 | 0.160 |
Why?
|
| Alcoholism | 3 | 2011 | 188 | 0.160 |
Why?
|
| Tryptophan Oxygenase | 2 | 2019 | 10 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 61 | 0.150 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 1587 | 0.150 |
Why?
|
| Enzyme Assays | 1 | 2019 | 18 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2013 | 1245 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 156 | 0.150 |
Why?
|
| Radiation, Ionizing | 1 | 2018 | 123 | 0.130 |
Why?
|
| Immune Tolerance | 1 | 2020 | 375 | 0.130 |
Why?
|
| Disease Models, Animal | 6 | 2020 | 2495 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 188 | 0.120 |
Why?
|
| Rats | 6 | 2013 | 4072 | 0.110 |
Why?
|
| Lumbar Vertebrae | 2 | 2009 | 358 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 224 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 641 | 0.110 |
Why?
|
| SOX9 Transcription Factor | 1 | 2014 | 28 | 0.110 |
Why?
|
| Blotting, Southern | 1 | 2014 | 110 | 0.110 |
Why?
|
| Male | 13 | 2020 | 44557 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2014 | 122 | 0.110 |
Why?
|
| Chickens | 1 | 2014 | 206 | 0.110 |
Why?
|
| Neoplasms | 3 | 2020 | 3169 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2014 | 43 | 0.100 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 309 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2015 | 3502 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 105 | 0.100 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 69 | 0.100 |
Why?
|
| DNA Primers | 1 | 2014 | 531 | 0.100 |
Why?
|
| Aging | 2 | 2016 | 727 | 0.100 |
Why?
|
| Ketorolac | 1 | 2013 | 6 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 2755 | 0.100 |
Why?
|
| Fractures, Malunited | 1 | 2012 | 6 | 0.100 |
Why?
|
| Prognosis | 2 | 2017 | 3911 | 0.090 |
Why?
|
| Bone Remodeling | 2 | 2009 | 21 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 63 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 3 | 2016 | 3435 | 0.090 |
Why?
|
| Biomechanical Phenomena | 2 | 2013 | 489 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 249 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2010 | 283 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1799 | 0.080 |
Why?
|
| Humans | 16 | 2025 | 93515 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 231 | 0.080 |
Why?
|
| Biomarkers | 2 | 2018 | 1910 | 0.080 |
Why?
|
| Alcohols | 1 | 2009 | 14 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2020 | 2121 | 0.070 |
Why?
|
| Bone Resorption | 1 | 2009 | 43 | 0.070 |
Why?
|
| Spine | 1 | 2010 | 150 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1741 | 0.070 |
Why?
|
| Gene Expression | 2 | 2010 | 1301 | 0.070 |
Why?
|
| Wound Healing | 1 | 2010 | 373 | 0.070 |
Why?
|
| Weight Gain | 1 | 2008 | 128 | 0.070 |
Why?
|
| Cytokines | 1 | 2011 | 863 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1660 | 0.060 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 554 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 526 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2025 | 110 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1518 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2025 | 422 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2018 | 1524 | 0.050 |
Why?
|
| Aged | 4 | 2023 | 20434 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 144 | 0.040 |
Why?
|
| Synapses | 1 | 2022 | 274 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2020 | 106 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2023 | 697 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 517 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 660 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 7061 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 305 | 0.030 |
Why?
|
| Immune Evasion | 1 | 2018 | 37 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 315 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2017 | 170 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2018 | 674 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2015 | 9099 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2018 | 299 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1906 | 0.030 |
Why?
|
| Catalysis | 1 | 2015 | 216 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1170 | 0.030 |
Why?
|
| Immunity | 1 | 2015 | 153 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1723 | 0.030 |
Why?
|
| Middle Aged | 3 | 2020 | 27573 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 2303 | 0.030 |
Why?
|
| Adult | 3 | 2020 | 27918 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 1061 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 102 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 304 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2012 | 23 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1103 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 2017 | 0.020 |
Why?
|
| Tensile Strength | 1 | 2012 | 86 | 0.020 |
Why?
|
| Mutation | 1 | 2023 | 4272 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1338 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 2026 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1275 | 0.020 |
Why?
|
| Immunoassay | 1 | 2011 | 99 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 307 | 0.020 |
Why?
|
| Temperance | 1 | 2010 | 6 | 0.020 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2010 | 42 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 917 | 0.020 |
Why?
|
| Female | 3 | 2020 | 48702 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2009 | 25 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2009 | 11 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2009 | 10 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 884 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 128 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 276 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2009 | 273 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1914 | 0.020 |
Why?
|
| Acute Disease | 1 | 2009 | 841 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 408 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 960 | 0.010 |
Why?
|
| Inflammation | 1 | 2011 | 1050 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 5410 | 0.010 |
Why?
|
| Lung | 1 | 2011 | 1366 | 0.010 |
Why?
|